KLC
ANIK icon

Kent Lake Capital’s Anika Therapeutics ANIK Stock Holding History

Kent Lake Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-98,570
Closed -$2.2M – 40
2022
Q2 		$2.2M Buy
+98,570
New +$2.2M 1.21% 28

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Kent Lake Capital's ANIK Position: Q3 2022 in Review

Kent Lake Capital sold out of Anika Therapeutics (ANIK) in Q3 2022, closing a stake of 98,570 shares — an estimated $2.2M sold.

Kent Lake Capital first reported a position in ANIK in Q2 2022 and held it in 1 quarter. The position peaked at $2.2M in Q2 2022. 121 funds tracked by Wall St. Rank hold ANIK as of Q3 2022.

  • Kent Lake Capital reported no remaining Anika Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Kent Lake Capital sold 98,570 Anika Therapeutics shares in Q3 2022, an estimated $2.2M.
  • Kent Lake Capital first reported a position in Anika Therapeutics in Q2 2022 and held it in 1 quarter.
  • Kent Lake Capital's Anika Therapeutics position peaked at $2.2M in Q2 2022.
  • 121 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2022.

Based on Kent Lake Capital's 13F filing for Q3 2022, filed 14 Nov 2022.